Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HARVARD BIOSCIENCE INC Director's Dealing 2021

Jun 15, 2021

34975_dirs_2021-06-15_a09471cf-b0b5-4b89-b292-cac29f8ba520.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2021-06-11

Reporting Person: Green James W (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-11 Common Stock A 109070 Acquired 2388848 Direct
2021-06-11 Common Stock F 48373 $7.64 Disposed 2340475 Direct

Footnotes

F1: On June 11, 2020, the Reporting Person was granted an award of 218,141 restricted stock units with performance based vesting conditions, which vest in equal installments on June 11, 2021, 2022 and 2023, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from June 11, 2020 to the earlier of (i) June 11, 2021 or (ii) upon a change of control (measured relative to the Nasdaq Biotechnology index). The target number of the restricted stock units that may be earned was reported on the date of grant; the maximum amount is 150% of the number then reported. As a result of the Issuer's performance based on such performance targets, the Reporting Person earned 150% of the target amount, subject to continuation of employment through the remaining vesting dates. Accordingly, the reported transaction reflects the acquisition of 109,070 additional performance restricted stock units earned above the target grant.

F2: Includes (a) 218,141 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, (c) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (c) 243,072 restricted stock units that will fully vest on July 8, 2021, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 605,035 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 755,116 shares of common stock beneficially owned by the Reporting Person.

F3: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on June 11, 2021.

F4: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above.